International medical case reports journal · 2025
Hepatotoxicity Induced by Adalimumab in Chronic Plaque Psoriasis Patient: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Algarzae Norah K, Alotaibi Hend M, Alajlan Ahmed H, AlSaleh Muneera R, Alsalman Alanoud A
Аннотация
INTRODUCTION: Adalimumab is a TNF-α antagonist used to treat psoriasis and rheumatologic conditions; it can rarely cause hepatotoxicity manifesting as elevated liver enzymes.
CASE PRESENTATION: Here, we present a case of a 24-year-old female with chronic plaque psoriasis with no history of liver disease or any risk factor for liver disease who developed a drug-induced liver injury upon treatment initiation with Adalimumab. This case report highlights the importance of monitoring liver function tests in patients receiving Adalimumab, early recognition, and prompt medication dosage adjustment or discontinuation. Early diagnosis and treatment of chronic plaque psoriasis is critical for improving prognosis, especially in the case of increased risk factors of liver disease due to the administration of Adalimumab.
CONCLUSION: Our case presented a patient with no history of liver disease; however, she developed a drug-induced liver injury. Therefore, this case report is the first to emphasize the need for early recognition of LFTs upon Adalimumab administration, and prompt medication dosage adjustment or discontinuation is essential in patients receiving Adalimumab.
CASE PRESENTATION: Here, we present a case of a 24-year-old female with chronic plaque psoriasis with no history of liver disease or any risk factor for liver disease who developed a drug-induced liver injury upon treatment initiation with Adalimumab. This case report highlights the importance of monitoring liver function tests in patients receiving Adalimumab, early recognition, and prompt medication dosage adjustment or discontinuation. Early diagnosis and treatment of chronic plaque psoriasis is critical for improving prognosis, especially in the case of increased risk factors of liver disease due to the administration of Adalimumab.
CONCLUSION: Our case presented a patient with no history of liver disease; however, she developed a drug-induced liver injury. Therefore, this case report is the first to emphasize the need for early recognition of LFTs upon Adalimumab administration, and prompt medication dosage adjustment or discontinuation is essential in patients receiving Adalimumab.